Introduction
Materials and Methods
Study Design
Study Measures
Magnetic Resonance Imaging (MRI) at Baseline and Follow-Up (Short Term and Long Term)
Angiographic Procedure
Clinical Assessment at Baseline and Follow-Up (Short Term and Long Term)
Statistical Analysis
Results
Patient demographics, previous treatment, symptoms | Procedural characteristics | |||||
---|---|---|---|---|---|---|
Patient | Age | Previous treatment | Main symptoms | Catheter | UAE material | Hospital stay |
1 | 33 | Hormonal (oral) | BRS + WTC | 4Fr sheath + C2 | Microspheres 900–1100 µm | 1 |
2 | 37 | NR | AUB + WTC | 4Fr sheath + C2 | Super-selective. Microspheres 500, 700, 900 µm (only left side) | 1 |
3 | 33 | Tranexamic acid, ulipristal. Myomectomy 2007 and 2015 | BRS + WTC | 4Fr sheath + C2 | Microspheres 700, 900, 1300 µm and 700 µm PVA | 1 |
4 | 45 | NR | BRS | 4Fr sheath + C2 | Microspheres 700–900 µm | 1 |
5 | 38 | Hormonal (oral) | P | 4Fr sheath + C2 | Microspheres 500, 900 µm | 1 |
6+ | 47 | NR | AUB + BRS | 4Fr sheath +C2 | Microspheres 700, 900, 1200 | 1 |
7+ | 42 | No | AUB | 4Fr sheath + C2 | Microspheres 700–900 µm and 900–1200 µm | 3 |
8+ | 33 | Hormonal (oral) | P + AUB | 4Fr sheath + C2 | Microspheres 700–900 µm | 1 |
Median (range) | 37.5 (33–47) | 1.0 (1–3) |
Imaging Results
Baseline | 3-Month follow-up | |||||||||
---|---|---|---|---|---|---|---|---|---|---|
Patient | Grade | Size (cm) | Volume (cm3) | Body fibroid Volume (cm3) | Size (cm) | Volume (cm3) | Volume decrease | Infarction rate | Body fibroid volume reduction |
Body fibroid
Infarction rate
|
Patients with solitary cervical leiomyomata
| ||||||||||
1 | 3 | 8.4 × 8.6 × 7.8 | 294.86 | – | 6.4 × 6.7 × 5.5 | 123.41 | 58.1% | 50% | NA | NA |
2 | 3 | 5.9 × 6.1 × 5.6 | 105.47 | – | 4.4 × 4.9 × 5.0 | 56.41 | 46.5% | 95% | NA | NA |
3 | 3 | 7 × 8×12.8 | 375.1 | – | 5.7 × 8.1 × 11.5 | 277.85 | 25.9% | 80% | NA | NA |
4 | 3 | 6.0 × 5.6 × 5.1 | 89.67 | – | 4.9 × 4.1 × 3.8 | 39.95 | 55.5% | 90% | NA | NA |
5 | 1 | 5.8 × 4.3 × 4.1 | 53.50 | – | 4.4 × 4.1 × 3.6 | 33.98 | 36.5% | 100% | NA | NA |
Median (range) | 105.5 (53.5–375.1) | 56.4 (34.0–277.9) | 46.5% (25.9–58.1) | 90% (50–100) | ||||||
Patients with concurrent non-cervical fibroid disease | ||||||||||
6 | 2 | 7.2 × 5.2 × 5.4 | 105.80 | 837.71 | 5.0 × 4.4 × 6.7 | 77.13 | 27.1% | 100% | 21.6% | 95% |
7# | 3 | 11.5 × 9.7 × 10.0 | 583.74 | 1: 9.18 2: 14.13 3: 3.3 | 7.5 × 8.0 × 6.9 | 216.65 | 62.9% | 40% | 1: 73.4% 2: 37.4% 3: 48.5% | 1:100% 2:100% 3:100% |
8# | 3 | 3.4 × 3.6 × 4.6 | 29,46 | 1:6.88 2: 59.77 | 3.4 × 3.2 × 4.1 | 23.34 | 20.8% | 60% | 1: 34.0% 2: 26.1% | 1: 90% 2: 0% |
Median (range) | 105.8 (29.5–583.7) | 77.1 (23.3–216.7) | 27.1% (20.8–62.9) | 60% (40–100) | ||||||
Total of patients
| ||||||||||
Total median (range) | 105.6 (29.46–583.8) | 66.8 (23.3–277.9) | 41.5% (20.8–62.9) | 85% (40–100) |